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Abstract
Background: DNA repair pathways, cell cycle arrest checkpoints, and cell death induction are present in cells to
process DNA damage and prevent genomic instability caused by various extrinsic and intrinsic ionizing factors.
Mutations in the genes involved in these pathways enhances the ionizing radiation sensitivity, reduces the
individual’s capacity to repair DNA damages, and subsequently increases susceptibility to tumorigenesis.
Body: BRCA1 and BRCA2 are two highly penetrant genes involved in the inherited breast cancer and contribute to
different DNA damage pathways and cell cycle and apoptosis cascades. Mutations in these genes have been
associated with hypersensitivity and genetic instability as well as manifesting severe radiotherapy complications in
breast cancer patients. The genomic instability and DNA repair capacity of breast cancer patients with BRCA1/2
mutations have been analyzed in different studies using a variety of assays, including micronucleus assay, comet
assay, chromosomal assay, colony-forming assay, γ -H2AX and 53BP1 biomarkers, and fluorescence in situ
hybridization. The majority of studies confirmed the enhanced spontaneous & radiation-induced radiosensitivity of
breast cancer patients compared to healthy controls. Using G2 micronucleus assay and G2 chromosomal assay,
most studies have reported the lymphocyte of healthy carriers with BRCA1 mutation are hypersensitive to invitro
ionizing radiation compared to non-carriers without a history of breast cancer. However, it seems this approach is
not likely to be useful to distinguish the BRCA carriers from non-carrier with familial history of breast cancer.
Conclusion: In overall, breast cancer patients are more radiosensitive compared to healthy control; however,
inconsistent results exist about the ability of current radiosensitive techniques in screening BRCA1/2 carriers or
those susceptible to radiotherapy complications. Therefore, developing further radiosensitivity assay is still
warranted to evaluate the DNA repair capacity of individuals with BRCA1/2 mutations and serve as a predictive
factor for increased risk of cancer mainly in the relatives of breast cancer patients. Moreover, it can provide more
evidence about who is susceptible to manifest severe complication after radiotherapy.
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Introduction
The genomic content of cells is constantly exposed to
extrinsic and intrinsic factors leading to DNA damage
and genomic instability. These damages can affect the
integrity of one or both strands of a DNA molecule. In
this case, they are called single-strand and double-strand
DNA breaks, respectively [1]. Double-strand breaks
(DSBs) are considered as much severe and harmful dam-
ages, which can generate extreme and disruptive muta-
tions [2]. Several cascades of cellular events comprising
DNA repair pathways, cell cycle arrest, and apoptosis
are important to rectify DNA damage, prevent uncon-
trolled cell dividing and passing unrepair DNA damages
to the daughter cells. People with mutations in the genes
involved in these pathways are more sensitive to radi-
ation (radiosensitive) and have an impaired proliferative
capacity after exposure to DNA damaging agents; there-
fore, they are at higher risk of cancer development com-
pared to a normal population.
Breast cancer is the most common cancer and the first
leading cause of cancer-related death in women world-
wide [3]. While majority of breast cancers occur sporad-
ically, approximately 5-10 % of them follow a hereditary
pattern, meaning that certain mutated genes that are
passed from parents to children contribute to the devel-
opment of breast cancer [4]. Several studies demon-
strated an increased level of radiosensitivity among
breast cancer patients. They are more radiosensitive
comparing to other cancer types, like oesophageal cancer
as well [5]. In this malignancy, BRCA1 and BRCA2 are
among the high penetrant susceptibility genes and muta-
tions in these genes have been associated with hypersen-
sitivity and genetic instability [6]. Studies have reported
that BRCA1−/− mouse embryonic fibroblasts (MEFs) and
human breast cancer line, HCC1937 [7, 8], are highly
sensitive to ionizing radiation and retrovirally transfect-
ing these cells with wild-type BRCA1 diminished the
ionizing radiation sensitivity and improved the efficiency
of DSBs repair [9]. Likewise, the clinical studies stated
BRCA1/2 mutation carriers are more radiosensitive than
healthy control [5, 10, 11] and manifest more severe
radiotherapy complications [12, 13] due to having de-
fective DNA damage repair system.
Currently, the most reliable test for pre-screening the
BRCA1/2 carriers is limited to the full sequencing of the
genes. However, this technique is time-consuming, diffi-
cult, and costly and, up to 30% of mutations cannot be
detected properly. Moreover, one-third of all breast can-
cer occurs within the families are not related to either
BRCA1 or BRCA2, indicating that other low penetrate
genes are involved in the development of familial breast
cancer. Evaluating the DNA repair capacity may serve as
a biomarker to identify individuals at increased risk of
breast cancer and act as a pre-screening test in women
with a family history of breast cancer. To date, several
studies have utilized different types of assays to evaluate
the radiosensitivity in BRCA1/BRCA2-associated breast
cancer patients compared to sporadic one and healthy
individuals. Here, we first give an overview of the contri-
bution of BRCA1/2 to radiosensitivity through regulating
the DNA repair pathways, and cell cycle checkpoint and
apoptosis cascades. We then discuss the clinical and
functional assays for determining the radiosensitivity
capacity of sporadic and familial breast cancer patients.
DNA repair pathways and cell cycle mechanisms
DSBs are regarded as severe and harmful damages and
can generate extreme and disruptive mutations if remain
unrepaired [2]. Cells have developed two main repair
pathways, homologous recombinant (HR) and non-
homologous end-joining (NHEJ) repair pathway, to deal
with this type of DNA damage.
HR repair pathway exclusively takes place in the late S
and G2 phases of the cell cycle. This pathway requires
an unharmed homologous DNA sequence located in the
sister chromatin as a template for the synthesis of the
damaged region. The overall process starts with the rec-
ognition of the DSB region by the Mre11-RAD50-Nbs1
(MRN) complex (Fig. 1). Next, ATM is recruited to the
DNA damage location, which in turn facilitates the re-
cruitment of other crucial proteins, including ATR,
CHEK2, BARD1, BRCA1, BRCA2, and RAD51 [14]. Mu-
tations in genes encoding these proteins have been asso-
ciated with the increased risk of breast cancer.
While HR repair is considered as the most accurate and
error-free pathway, NHEJ is a less precise repair pathway
and is mainly activated in phases G0 and G1, where HR is
not available. NHEJ also functions as a backup repair
pathway in case of defects in components of the HR path-
way [15]. The general mechanism involves the recruit-
ment of DNA dependent protein kinases (DNA-PK) [16],
following the attachment of Ku proteins on the broken
ends of DNA [17] (Fig. 2). Afterward, a DNA polymerase
fills the gaps that have been produced as a result of the
endonuclease activity of Artemis protein. Finally, a DNA
ligase IV joins the DNA ends with the help of its cofactors,
XRCC4 and XLF [15].
Every event that has been described above happens
during the cell cycle (Fig. 3). While a normal cell cycle is
vital for the development and survival of organisms, a
defective one inflicts irreparable losses. To prevent such
unwanted destiny, cells have developed cell cycle check-
points to allow the progression of the cycle when the
events of each phase are completed properly or arrest
the cycle once there is DNA damage. The main regula-
tors of cell cycle checkpoints are cyclin-dependent ki-
nases (CDK), which are activated in the presence of
cyclin proteins [18].
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In the G1 phase, two complexes of CDK4/6-Cyclin D and
CDK2-Cyclin E, permit the cells to enter the S phase by
phosphorylating the transcriptional repressors Retinoblast-
oma (Rb) and p107/p130 proteins, a process which eventu-
ally leads to initiation of DNA replication (Fig. 3). In the
case of DSB, the cycle is halted by activation of ATM and
phosphorylation of CHK2, which in turn phosphorylate
cdc25A and p53 in order to inhibit the cell from entering
the S phase [19]. Cells that have successfully passed the G1
checkpoint, start their DNA duplication in phase S. A DNA
damage in this stage leads to activation of the ataxia-
telangiectasia mutated and Rad3 related kinase (ATR) and
chk1 kinase to stabilize p53 and degrade cdc25A [18, 20].
Prior to the mitosis, cells go through the G2 phase to
grow and produce the proteins necessary for the division
process (Fig. 3). In this phase, CDK1-cyclin B is the main
regulator and the interruption of the cell cycle in the
presence of DNA damage particularly relies on ATR and
chk1 rather than ATM and CHK2 proteins [18].
The activity of each component in DNA repair path-
ways and cell cycle checkpoints results in the progres-
sion of cells into division or apoptosis. However, in
cancerous cells, these mechanisms do not function prop-
erly and lead to harmful consequences.
BRCA1
Frequency
Mutation in BRCA1 gene is considered as the main cause
of hereditary breast cancer, and it is responsible for 40–
45% of total hereditary breast cancer development [21].
Over 858 BRCA1 mutations have been confirmed to have




































Fig. 1 Homologues recombinant DNA repair system. The overall process starts with the recognition of the DSB region by the Mre11-RAD50-Nbs1
(MRN) complex. Next, ATM phosphorylates γH2AX, MDC1, and RNF8, which subsequently initiate the formation of BRCA1–abraxas–RAP80
complex. Later, BRCA1 via cooperating with MRN forms a complex with CtIP, to promote 5′-end resection in the early steps of the synthesis-
dependent strand annealing (SDSA) pathway of HR. BRCA1 interacts with PALB2 and BRCA2 to recruit RAD51, an essential mediator in the HR
repairing pathway. The formation of BRCA1- PALB2- BRCA2 complex is relying on CHK2-mediated phosphorylation of S988 on BRCA1
Sadeghi et al. Biological Procedures Online           (2020) 22:23 Page 3 of 28
Women with an inherited BRCA1 mutation have a life-
time risk of 70–80% of developing breast cancer and 37–
62% of developing ovarian cancer [22]. Moreover, there
are other types of cancers related to the BRCA1 muta-
tions, such as fallopian tube and peritoneal cancer in
women and prostate and breast cancer in men [23, 24].
BRCA1 mutated breast cancer is known to be
triple-negative breast cancers (TNBC), characterized
by negative estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor re-
ceptor 2 (HER2). However, they manifest the same
immunohistochemical profiles for the positive
Fig. 2 Non-homologous end-joining DNA repair system. The general mechanism involves the recruitment of DNA dependent protein kinases (DNA-
PK), following the attachment of Ku proteins on the broken ends of DNA. Afterward, a DNA polymerase fills the gaps that have been produced as a
result of the endonuclease activity of Artemis protein. Finally, a DNA ligase IV joins the DNA ends with the help of its cofactors, XRCC4, and XLF





















Fig. 3 An overview of the cell cycle regulation. Cyclin D with the cooperation of CDK4/6 regulates the events is the early G1 phase. Cyclin E-
CDK2 are responsible to initiate S phase, Cyclin A with CDK2 and then CDK1 involve in the completion of S phase for entry into mitosis, and
Cyclin B-CDK1 fascinate this entry
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Fig. 4 The gene structure of BRCA1 (a) and the overall contribution of this protein (b), mainly in the cell cycle (c) and apoptosis pathways (d)
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expression of cytokeratin (CK) 5/6 and CK14 with
sporadic basal carcinoma [25].
Gene structure
BRCA1 is located on chromosome 17 and consists of 22
coding exons, which exon 11 is considered as the largest
one, encoding over 60% of total 1863 amino acids
encoded by the BRCA1 gene (Fig. 4a). BRCA1 gene is
responsible for the translation of full-length BRCA1 pro-
tein [26] and over 4000 genetic variants of this gene have
been functionally identified [27]. The mature and full-
length of BRCA1 protein is located in the nucleus and
consists of several functional domains, including N-
terminal zinc-binding RING finger domain (amino acids
#10-109), BRCA1 C-terminal (BRCT) domain (amino
acids #1640-1729, #1760-1821), two nuclear localization
signals (NLS), a coiled-coiled domain (amino acids
#1367-1437), and Serine– Glutamine (SQ) cluster
(amino acids #1280-1524) [28] (Fig. 4a).
The zinc-binding RING finger motif is the main func-
tional part of BRCA1 and it is important for E3-
ubiquitin ligase activity of this protein. This motif het-
erodimerizes with BRCA1-Associated RING Domain 1
(BARD1) and the tandem BRCT domain, resulting in
various protein-protein interactions through binding to
phosphorylated serine [29].
BRCT domain appears as a tandem repeat in BRCA1
gene and it is responsible for the phosphoprotein inter-
actions between BRCA1 and other phosphorylated pro-
teins involved in DNA damage response, such as CtIP,
BRIP1, and Abraxas [30, 31]. Shakya et.al demonstrated
that the BRCT domain is critical for the genome stability
function of BRCA1, and S1598F point mutation in this
domain disrupts the genomic stability function of
BRCA1 and causes tumors development like when
BRCA1 is completely deactivated [32]. Moreover, a
recent study revealed that the interaction between this
domain and mTORC2 impairs Akt activation, which
is necessary for the proliferation of cancer cells [33].
Several BRCT-associated mutations have been recog-
nized, which are able to disturb different functions of
this protein, including damage foci localization, pro-
tein stability, and resection-dependent Homology di-
rected repair (HDR) and Single Strand Annealing
(SSA) [34–37].
The region between the RING and BRCT domains
is called the central region of BRCA1. The central re-
gion was not studied properly as two previous do-
mains [38]. Recently Lin et.al reported this region
contains nine highly-conserved motifs, which are ne-
cessary for DNA repair activity of BRCA1 and the de-
letion of these motifs could decrease cell viability
following cisplatin treatment [39].
The transportation of BCRA1 from the cytosol to
the nucleus is controlled by two NLS domains, which
are recognized by the importin-α machinery. Muta-
tion in the NLSs domain causes accumulation of
BRCA1 in the cytosol and reduce the tumor suppres-
sor activity of this protein [40].
The coiled-coil domain of BRCA1 is located in exons
11-13 of BRCA1 and interacts with the coiled-coil do-
main of PALB2 during the HR DNA repair system [41,
42]. The SQ cluster also contributes to HR and contains
several serine and threonine residues that can be phos-
phorylated by ATM and ATR [43, 44].
Function
Several functions have been attributed to BRCA1 pro-
tein, including transcription-coupled repair, regulation
of transcription, remodeling of chromatin, apoptosis,
and ligation of ubiquitin [44] (Fig. 4b). However, the
well-known function of BRCA1, acting as a tumor sup-
pressor, is related to the role of BRCA1 in promoting
genomic stability [45, 46]. In order to regulate genomic
stability, BRCA1 contributes to DNA repairing pathways,
participates in DNA damage-induced cell cycle check-
point mechanisms (Fig. 4c), and induce apoptosis cas-
cade activation (Fig. 4d) [45]. Moreover, recent
evidence demonstrated BRCA1 contribution to gen-
omic stability maintenance is associated with the pre-
vention of tandem duplication [47] and RNA-DNA
hybrid (R loop) processing [48].
DNA repair
Several studies have reported that cells with defective
BRCA1 gene are hypersensitive to DNA damaging
agents, such as IR, UV, and alkylating agents. These
defective BRCA1-cells fail to repair DNA damages
properly, indicating the essential role of BRCA1 in
the DNA repair system [9]. As discussed earlier,
NHEJ and HR are two main DSB repairing pathways
in every organism. BRCA1 influences the cellular
choice to proceed toward NHEJ or HR pathways to
repair the damages in DNA.
Role of BRCA1 in HR
Many studies demonstrated the direct role of BRCA1
in the HR pathway, as BRCA1 deficient cells showed
severe impaired HR-mediated DSB repairing (Fig. 1)
[14, 49]. Following DSB in DNA, BRCA1 binds to
DSB through abraxas–RAP80 macro-complex, which
induces ubiquitination of histones at DNA DSBs [14].
The formation of BRCA1–abraxas–RAP80 complex is
dependent on the phosphorylation of histone H2AX
(γH2AX), the mediator of DNA damage checkpoint
protein 1 (MDC1) and RING finger protein 8 (RNF8)
by ATM [50]. Afterward, BRCA1 via cooperating with
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Mre11, Rad50, and Nbs1 (MRN) forms a complex
with CtIP, to promote 5′-end resection in the early
steps of the synthesis-dependent strand annealing
(SDSA) pathway of HR [51, 52]. Although the
BRCA1–CtIP complex has been shown to be critical
for the HR pathway in chicken DT40 cells, another
research reported this interaction is not necessary for
resection-mediated DNA repair or tumor suppression
in mammalian cells [53]. In the following, BRCA1 in-
teracts with PALB2 and BRCA2 to recruit RAD51, an
essential mediator in the HR repairing pathway. The
formation of BRCA1- PALB2- BRCA2 complex is
relying on CHK2-mediated phosphorylation of S988
on BRCA1 [54]. Lack of BRCA1 or mutation in S971,
which corresponds to human S988, breaks apart the
PALB2-BRCA2 complex, which leads to the abrogated
HR repair process and development of mammary and
endometrial tumors in exposure to DNA damaging
agents [55]. The function of BRCA1 in HR is distinct
from its other functions in the DDR. Cells expressing
BRCA1 mutant S988A have defective HR repair path-
way, although the checkpoint regulation or resistance
to ionizing radiation remains intact [56].
Furthermore, a recent study found that T1394 phos-
phorylation residues are influential for BRCA1-PALB2
interaction and any mutation in this site can partially
impair HR pathway activity [57].
The BRCA1–BACH1 complex also contributes to
the HR pathway. This complex is not HR restricted
and involves many DNA repair pathways, such as cell
cycle checkpoint, and DNA interstrand crosslink
(ICL) repair [58]. BACH1 is one of the Fanconi
anemia (FA) proteins that interact with the BRCT do-
main of BRCA1 through phosphoserine [59]. Muta-
tion in BACH1 or in BRCT domain that could
disrupt the interaction between BRCA1 and BACH1,
affect the HR pathway, delay DNA repair, and finally
increase the risk of breast cancer [60, 61].
Role of BRCA1 in NHEJ
BRCA1 contribution to the NHEJ repair pathway has
been reported in different studies; however, there are
contradictory results regarding this function. The role
of BRCA1 in NHEJ has been initially determined in
MEFs, indicating a significantly reduced end-joining
activity in BRCA1 depleted MEFs comparing to the
wild-type cells [62]. Later, other studies have reported
the same decreased activity of the NHEJ pathway in
BRCA1-deficient HCC1937 [63], and lymphoblastoid
cell lines derived from breast cancer patients [64, 65].
Further studies demonstrated BRCA1 is required for
precise end-joining, as knockdown of this gene signifi-
cantly reduced the ability of cells in precise DNA re-
pair mechanisms [66]. A similar result has been
obtained, when other C-NHEJ components, including
Ku70, XRCC4, and Ligase IV were knocked down
[66]. Moreover, a reduced level of end-joining effi-
ciency has been reported in BRCA1Δ14– 15 and
BRCA1Δ17–19 splicing variants, suggesting that these
splicing variants may have a prevailing negative effect
on the efficiency of C-NHEJ [67].
In contrast, some evaluations concluded that BRCA1
is not part of NHEJ pathway in BRCA-deficient
HCC1973 cell lines using pulsed-field gel electrophoresis
[68, 69] and further showed sporadic breast cancer cells
has intact NHEJ activity in DSB repairing [70].
Cell cycle checkpoints
Cell cycle checkpoints have a critical role in cell survival.
During DNA damage, BRCA1 contributes to cell survival
through activating DNA damage checkpoints occurring
in G1/S, intra-S, and G2/M phases (Fig. 4c). Eventually,
the activated checkpoints block the cell cycle progres-
sion in the presence of DNA damage and prohibit the
cell cycle process until the damage is fully repaired.
Role of BRCA1 in G1/S checkpoint
In 2004 Fabbro et al. reported cells with knockdown
BRCA1 failed to undergo cell cycling progression
through G1/S checkpoint, indicating the important
role of BRCA in this cell cycle phase [71]. The au-
thors reported that BRCA1 mediates the phosphoryl-
ation of p53 by ATM during DNA damage and
thereby, induce the expression of cyclin inhibitor p21.
In their study, BRCA1 induced phosphorylation of
p53 in response to both IR and UV DNA damage;
however, the role of BRCA1 in G1/S arrest was
merely found following IR damage. Additionally, a re-
cent study reported that UV exposure also disrupts
the G1/S cell cycle checkpoint in primary fibroblasts
from individuals with a BRCA1 +/- genotype [72].
Role of BRCA1 in S-phase checkpoint
S-phase checkpoint is another cell cycle checkpoint,
which inhibits the cell cycle progression following
DNA damage. The impaired activity of S-phase
checkpoints in BRCA1 deficient HCC1937 cells dur-
ing DNA damage and its restoration to normal activ-
ity by functional complementation of the BRCA1
gene indicates that BRCA1 has a critical role in S-
phase checkpoint activity [73].
In response to DNA damage, ATM and ATR are acti-
vated and promote the kinase activity of Chk1 and
Chk2. These two checkpoint kinases regulate the Cdc25
phosphatase family and this family (A/B/C) controls
cyclins and cyclin-dependent kinases’ activity during S-
phase progression [19]. It seems that BRCA1
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involvement in S-phase checkpoint is mediated through
regulation of Chk1 kinase activity.
Moreover, activation of S-phase checkpoint is
dependent on the phosphorylation of ser1387 of BRCA1
via ATM, indicating the possible role of phosphorylated
BRCA1 in recruiting the other regulating components in
the signal cascade [73]. Furthermore, BRCA1 might
regulate the activation of ATM following DNA damage
during S-phase. Studies have demonstrated that BRCA1
interacts with the MRN complex, which monitors cells
for DSBs and activates ATM directly [74, 75].
Besides, a recent study suggested that in response to
DNA damage, pCAF and GCN5 acylate the lysine 830 of
BRCA1 to activate this protein. SIRT1, on the other
hand, inhibits the activity of BRCA1 through the deace-
tylation of lysine 830. BRCA1 and SIRT1 form a recipro-
cal loop to regulate the intra-S-phase checkpoint,
maintaining genome stability and, thereby preventing
tumorigenesis [76].
The BRCA1–BACH1 is another complex that is in-
volved in the S phase. This interaction can be imme-
diately detected during S checkpoint and it is
necessary for stalling replication forks due to DSBs or
DNA lesions [77, 78]. Mutation in the BRCT domain
disturbs the proper connection between BRCA1 and
BACH1, which results in delayed entry into the S
phase of the cell cycle, defective DNA repair, and
breast cancer development [60].
Role of BRCA1 in G2/M checkpoint
Similar to G1/S and S-phase checkpoints, G2/M check-
point is also activated in case of DNA damage, arresting
the cell cycle process, and cell division.
It has been reported that intact BRCA1 is essen-
tial for both initial and the maintenance of the G2/
M checkpoint function, while BRCA2 and PALB2
are only responsible for maintaining the cell arrest
[79]. Following DNA damage, abraxas–RAP80
macro-complex controls the recruitment of DNA
repair proteins like BRCA1 to the sites of DNA
damage and BRCA1–abraxas–RAP80 complex acti-
vates the G2/M phase cell-cycle checkpoints and
cause CHK1 phosphorylation later [80]. In addition,
CtIP/BRCA1 only exists in the G2 phase and has
been shown to be critically involved in the G2/M
transition phase checkpoint activation and CHK1
phosphorylation in response to the DNA damage
[81, 82]. However, damage-induced G2 accumula-
tion checkpoint is controlled by BRCA1–BACH1
complex, not CtIP/BRCA 1[82]
Apoptosis
Various studies revealed the consequential role of
BRCA1 in inducing apoptosis through different
mechanisms (Fig. 4d). 1) BRCA1 is known to be a
nuclear-cytoplasmic shuttling protein and BARD1 is re-
sponsible for transporting BRCA1 to nuclear. The
BRCA1-depended apoptosis occurs when the BRCA1-
BARD1 complex is disrupted and BRCA1 accumulate in
the cytoplasm [83, 84]. 2) BRCA1 also mediates apoptosis
through regulating the p53 inducible gene 3 (PIG3) ex-
pression [85]. PIG3 is a downstream protein of p53 and it
is involved in the p53-dependent apoptosis pathway.
Zhang et al. demonstrated the significant association be-
tween PIG3/BRCA1 expression and better survival of
breast cancer patients [85]. 3) A correlation between
BRCA1 and impaired tumor necrosis factor (TNF)-α pro-
duction have been reported, which is an apoptotic inducer
factor [86]. Moreover, Natriuretic peptide receptor 3 sup-
presses cytoplasmic BRCA1 and TNF-α and protects the
cardiomyocytes from cell death [87]. 4) X-linked inhibitor
of apoptosis (XIAP)-associated factor 1 (XAF1) is a tumor
suppressor protein that interacts with BRCA1 and makes
BRCA1 bind ERα and BRCA1-mediated K48 polyubiquiti-
nation of ERα, and finally induce BRCA1-mediated apop-
tosis [88]. 5) BRCA1 stimulates apoptosis through binding
to the inositol 1,4,5-trisphosphate receptors (IP3R), result-
ing in excessive calcium release and cell death [89]. IP3R
acts as a calcium channel and is activated by inositol tris-
phosphate. BRCA1 binds to IP3R, increase the sensitivity
of this receptor to its ligand, IP3, and subsequently in-
creases IP3R-mediated apoptotic calcium release [89]. 6)
BRAC1 expression could induce apoptosis in breast
cancer cell lines, in response to some stress stimuli,
such as serum deprivation. This apoptotic pathway is
independent of p53 function and proceeds through
-Ras/MEKK4/JNK and Fas-dependent signaling path-
way and activation of caspase 8 [90]. 7) Cytoplasmic
BRCA1 activates Growth Arrest and DNA Damage
45 (GADD45) sequences in a p53-independent man-
ner leading to cell death. GADD45 is a DNA
damage-responsive gene and function in DNA repair,
cell cycle checkpoint, and apoptosis pathways.
BRCA1 could either activate GADD45 through inter-
action with Oct-1 and CAAT motifs of this gene
[91] or suppress GADD45 through its interaction
with a novel zinc finger protein, ZBRK1 [92]. In re-
sponse to the DNA damage, BRCA1 induces the
p53- independent expression of GADD45 and subse-
quently activates the JNK/SAPK (c-Jun N-terminal




BRCA2 is another highly penetrant genes involved in
hereditary breast cancer susceptibility. BRCA2 mutation
increases the risk of breast cancer by 45-85% and
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ovarian cancer by 11-23% in the women population [94].
In addition, BRCA2 mutation has been found in 10% of
pancreatic cancers studied, associated with 10-fold raised
risk [95].
Unlike BRCA1 mutation carriers, the pathological
feature of breast cancer patients with a BRCA2 muta-
tion is usually similar to sporadic breast cancer. Al-
though BRCA1 is known to be TNBC, no significant
correlation between BRCA2 mutation and TNBC has
been reported [96].
Gene structure
BRCA2 was discovered in 1995 [97]. This large gene
contains 27 exons, which the most predominant muta-
tions occur in the exon 10 and exon 11 in the form of
insertion and deletion, resulting in several premature
stop codon ending and missense mutations [98].
BRCA2 gene encodes 3418 amino acids for different
functional domains (Fig. 5a). The N terminal region of
BRCA2 contains eight BRC repeats (amino acids #1009-
2082) with approximately 1000 amino acids. Although
the function of the N-terminal region is not clear yet, it
has been reported that BRC repeats in this region
are responsible for protein-protein interaction, espe-
cially between BRCA2 and RAD51. The c-terminal
region of BRCA2 contains BRCA2 DNA-binding do-
main (amino acids #2478-3185), which comprises a
helical domain (HD), three oligonucleotide/oligosac-
charide-binding (OB) folds and a Tower domain (T).
The helical domain encodes 190 amino acids and the
three OB domains named as OB1, OB2, and OB3
contain approximately 110 amino acids. The OB do-
mains are responsible for the high affinity of BRCA2
to ssDNA and dsDNA damage, and poly (ADP-Ri-
bose) [98, 99]. Moreover, there is a phenylalanine-
proline-proline (PhePP) motif in the C-terminal re-
gion (amino acids #2386–2411), beside the DNA-
binding domain. PhePP interacts with DMC1 and
FANCD2 thorough meiosis [100]. There are two
NLS motifs in the c–terminal of BRCA2 (amino
acids #3263-3269, #3381-3385), which are required
for transferring BRCA2 to the nucleus.
Function
BRCA2 participates in many biological activities. This
protein mainly acts as a tumor suppressor gene and pre-
vents cells from uncontrolled dividing and growth via
regulation of DNA repair, cell cycle, and cell death path-
ways (Fig. 5b).
DNA repair
Similar to BRCA1, BRCA2 plays a critical role in the
DNA repair system. The BRCA2 deficient cells demon-
strated genomic instability and caused mouse embryonic
lethality. Moreover, these cells are hypersensitive to
DNA damaging agents and fail to repair DNA damages
properly.
Role of BRCA2 in HR
BRCA2 contribution in the DNA repair system is mainly
through regulating the HR pathway [101] (Fig. 1). Yeast
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Fig. 5 The gene structure of BRCA2 (a) and the overall contribution of this protein (b), mainly in the cell cycle (c) and apoptosis pathways (d)
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BRCA2 is one of the crucial constituents of HR-
mediated DSB repair [102]. Bradley et al. demonstrated
the BRCA2-associated HR repair pathway is mediated by
the interaction of BRCA2 and RAD51 [102]. RAD51 in-
teracts with 300 residues of C-terminal region of BRCA2
and TR2 domain in C-terminal region stabilized the
RAD51 nucleofilaments, especially in response to nu-
cleotide depletion after treatment with a potent ribonu-
cleotide reductase inhibitor [103]. Deletion of C-
terminal region of BRCA2 or mutants like BRCA2
6174delT and 6158insT impair the RAD51- binding ac-
tivity of this domain, diminish the RAD51 recruitment
to the damage site, and thereby increase the risk of
tumor incidence in mice and early onset of breast and
ovarian cancers in human [104, 105]. Furthermore,
BRCA2 deficient cells are more sensitive to DNA dam-
ages agents, such as poly (ADP-ribose) polymerase
(PARP) inhibitors or radiation due to defective HR re-
pair pathway [106].
RAD51 also interacts with BRC motifs of BRCA2
[107]. Point mutations in BRC motifs, especially those
associated with familial early-onset cancer, significantly
disturb the interaction between BRCA2 and RAD51.
Overexpression of BRC motifs interrupts the formation
of subnuclear foci during DNA damage and increases
the sensitivity of cells to the ionizing radiation [107,
108]. The affinities of BRC motifs to RAD51 protein are
varied. BRC1 is critical for the interaction between
BRAC2 to RAD5; however, BRC4 has a threefold stron-
ger ability to RAD51 compered to BRC1. G1529R muta-
tion, which belongs to the BRC4 region, is significantly
associated with the risk of familial breast cancer. BRC5
and BRC6 are not required for this interaction [109].
Normally, Cyclin A-CDK2 (or cyclin B-CDK1) phos-
phorylate Se3291 in the C-terminal region of BRCA2
and inhibit the RAD51 binding activity of this domain
and consequently, suppress HR pathway [110]. Never-
theless, following DNA damage, the phosphorylation is
halted and RAD51 is recruited to the BRCA2-containing
DNA repair foci. Cyclin D1 interferes with the phos-
phorylation of Ser3291 by A-CDK2 and fascinated the
recruitment of RAD51 to BRCA2 [111]. Overexpression
of cyclin D1 has been reported in several cancer types,
mainly familial breast cancer [112, 113]. Moreover, polo-
like kinase 1 (Plk) improves the RAD51 recruitment and
accumulation at the DNA damage site. Plk is a proto-
oncogene that phosphorylates RAD51 at Serin 14 and
BRCA2 facilitates this process. The Plk1 phosphorylates
Rad51 at T14 by CK2, which facilitates Rad51 binding to
Nbs1, and finally, increase the recruitment and accumu-
lation of RAD51 and promote HR [114]. Furthermore,
Ubiquitin-specific protease 21 (USP21) enhances the ef-
ficiency of interaction between BRCA2 and RAD51at the
DNA damage site through deubiquitylating and
stabilization of BRCA2. Deactivation of USP21 reduces
the HR activity and increases the DNA damage fre-
quency [115].
Although BRCA2 involvement in HR pathways is prin-
cipally dedicated to RAD51 binding, additional protein-
protein interactions are also involved. The BRC repeat
in the N-terminal region of BRCA2 interacts with
PALB2/FANCN, which physically links BRCA1 to
BRCA2 in a cell cycle-dependent manner. Mutation in
either BRCA2 or PALB2 is associated with reducing the
ability of cells in HR repairing and accordingly, increas-
ing the risk of breast cancer [116].
Role of BRCA2 in NHEJ
Although BRCA1 is involved in both HR and NHEJ re-
pair systems, there is no strong evidence for the contri-
bution of BRCA2 in NEHJ. Several studies reported that
BRCA2 has no effect on NHEJ.
Cell cycle checkpoints
The function of BRCA2 in controlling the cell cycle
checkpoints is less studied compared to the BRCA1 (Fig.
5c). Few researchers demonstrated that truncated
BRCA2 cells fail to block cell-cycle transitions during
DNA damage and induce enhanced susceptibility to
breast cancer, although its direct effect on cell cycle ar-
rest is controversial and it seems the protein might cause
cell cycle arrest as part of its main function in DNA re-
pair mechanism.
Role of BRCA2 in G1/S checkpoint
It is not clear whether BRCA2 directly patriciates in the
G1/S checkpoint. However, a recent study reported that
defective BRCA2 stimulates replication stress, which
causes DNA damage and G1 arrest in a p53-dependent
manner. The author showed that the p53 level was in-
creased in BRCA2 deficient cells and the G1 cell popula-
tion was reduced when p53 was abrogated [106].
Role of BRCA2 in S-phase checkpoint
For the first time, Zwet et al demonstrated that trans-
fecting the Chinese hamster cell V-C8 with human
chromosome 13, which contains BRCA2 gene, or mouse
BRCA2 cDNA, could rescue the RDS phenotype of V-
C8 cells [117]. This finding showed that BRCA2 involved
in S-phase, although the molecular mechanism behind
was not well determined. It was speculated that BRCA2
works with BRCA1 to control this cell cycle checkpoint
[118]. A recent observation found the specific expression
of BRCA2 in S-phase and its important role for genome
maintenance of S cells population, which directly medi-
ates the replication stress, a hallmark of pre-cancerous
lesions. BRCA2 expression in the S phase is stabilized by
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USP21, as USP21 loss reduces the expression of BRCA2
in this cell cycle stage [115].
Role of BRCA2 in G2/M checkpoint
Early studies reported that BRCA2 deficient mice have
intact G2/M in response to DNA damage, seems that
BRCA2 doesn’t control this cell cycle checkpoint. How-
ever, further studies demonstrated that BRCA2 deficient
mice had defective spindle assembly checkpoint, ac-
quired mutations in the components of the mitotic
checkpoint, such as p53, Bubl, and Mad3L, and had de-
fective mitotic checkpoints, all providing evidence for
the role of BRCA2 in G2/M regulation [119, 120]. In
contrary to BRCA1 which is involved in both initial and
the maintenance of G2/M checkpoint, BRCA2 appears
to be more important for the maintenance of this cell
cycle [79, 121]. Following ionizing radiation, the BRCA2
knockdown cells showed G2 checkpoint arrest; however,
over time, the cells overcame this checkpoint and en-
tered mitosis, suggesting that BRCA2 is required for the
G2 maintenance [79, 121]. BRCA2 mediates its function
by interacting with BRCA2-associated factor 35
(BRAF35), which is a novel protein that binds to cruci-
form DNA. The nuclear staining revealed the colocaliza-
tion of both BRAF35 and BRCA2 on mitotic
chromosomes, which was concurrent with the phosphor-
ylation of serine 28 (Ser-28) of histone H3 [122]. Fur-
thermore, the antagonistic antibodies against either
BRCA2 or BRAF35 delayed metaphase progression
[122]. Moreover, Futamura et al. showed the interaction
between BRCA2 and hBUBR1. hBUBR1 is a homolog of
S. cerevisiae mitotic checkpoint protein BUB1 and phos-
phorylate BRCA2 [123].
Apoptosis
There is sparse evidence about the direct role of BRCA2
in the induction of apoptosis (Fig. 5d). BRCA2 deficient
mice showed defective cellular proliferation and died in
utero [124] Moreover, transfecting Capan-1 cells, which
expresses only a COOH-terminal truncated BRCA2
inhibited tumor growth in animal models and negatively
regulated cell proliferation [125]. Further studies nomi-
nated TNF and TRAIL-R signaling pathways as potential
pathways behind this phenomenon. Anne M. Heijink
and his college performed a genome-wide functional
genetic screen and identified the gene mutations that
prevented cell death in BRCA2 siRNA silenced cells.
They further validated their data in multiple BRCA2
deactivated breast- and leukemic cell lines and reported
that deactivation of BRCA2 induces apoptosis through
TNFα signaling pathway in these cell lines via downreg-
ulation of TNF receptor 1 (TNF-R1) or its downstream
signaling component Sam68 [126]. In addition, another
new study revealed that BRCA2 induces cell apoptosis
through the TRAIL/TRAIL receptor signaling pathway
and caspase 8 recruitment, apart from other functions of
BRCA2 in cell cycle arrest and DNA repair [127]. How-
ever, inconsistent result was reported from a clinical
study, reporting no significant difference between cellu-
lar proliferation and apoptosis between hereditary (with
germline BRCA mutations) and sporadic (without BRCA
mutation) ovarian tumors [128].
Radiosensitivity assays in Breast Cancer
Micronucleus assay
Micronuclei (MNi) acts as a biomarker for chromosome
damage or entire chromosome loss. Therefore, in vitro
micronucleus (MN) assay was designed to detect the
genotoxic damage in the cells by scoring the presence of
MNi. This test is faster than the chromosome aberration
test as the population cells are in the interphase and the
scoring system could be done in automation rather than
manually [129].
The radiosensitivity capacity of the cells in different
cell cycles is not similar. In the G0 MN assay, blood is
irradiated, then cultured in the presence of phytohem-
agglutinin (PHA), resulting in the irradiation of T lym-
phocytes in the G0 phase. G0-based assays have the
precondition that all lymphocytes are in the same cell
cycle with G0-radiosensitivity. In contrast, in G2 MN
assay cells are treated with mitogen PHA before irradi-
ation. PHA stimulates T lymphocyte division and pro-
vides a population of cycling lymphocytes (G1, S1, G2,
and M phase) after 3 days of incubation when the blood
culture is irradiated [130]. In general, MNi is detectable
in dividing eukaryote cells only. This technique has been
further modified by Fenech and Morely, called
cytokinesis-block MN (CBMN), in order to score DNA
damaged in a once-divided binucleated cell, which are
the cells that can express MNi. In the CBMN technique,
cells are treated with cytochalasin B, which is an inhibi-
tor of cytokinesis in cell division and the visualized binu-
cleated cell are an indicator of cell that completed one
nuclear division [131].
Nine studies compared the RS of breast cancer pa-
tients with control individuals (Table 1). The majority of
studies (77.8%) reported that radiation-induced fre-
quency of micronucleus was significantly higher in
breast cancer group in comparison to control [5, 10, 11,
133, 135, 136, 145]. In contrast, Djuzenova et al. deter-
mined no significant difference between the level of
MNi in breast cancer patients and healthy participants
using G2 micronucleus test [12] and Francies et al. re-
ported breast cancer patients with luminal are more ra-
diosensitive compared to healthy control, while no
difference between those with triple-negative breast can-
cer and healthy control has been detected [132].
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Table 1 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using micronucleus assay








1. BC cases (34)
A. TNBC (17)
B. Luminal (17)
2. Healthy controls (17)
Lymphocyte 2 and 4 Gy
X-rays
Spontaneous RS
TNBC ↔ Healthy controls
Luminal ↔ Healthy controls
RS after radiation
2-Gy X-rays
TNBC ↔ Healthy controls
Luminal ↔ Healthy controls
4-Gy X-rays
TNBC ↔ Healthy controls





1. BC cases (83)
A. TNBC (17)
B. Luminal (66)
2. Healthy controls (90)
Lymphocyte 2 and 4 Gy
X-rays
Spontaneous RS
BC cases > Healthy controls
TNBC > Healthy controls
Luminal > Healthy controls
RS after radiation
2-Gy X-rays
BC cases > Healthy controls
TNBC ↔ Healthy controls
Luminal > Healthy controls
4-Gy X-rays
BC cases > Healthy controls
TNBC ↔ Healthy controls
Luminal > Healthy controls




1. BC cases (25)




BC case > Healthy controls
RS after radiation





1. BC cases (50)
2. Healthy controls (16)




BC cases ↔ Healthy controls
Slope of MN induction
BC cases ↔ Healthy controls




1. BC cases (91)




BC cases > Healthy controls
RS after radiation





1. BC cases (50)




BC cases > Healthy controls
RS after radiation
BC cases > Healthy controls




1. BC cases (130)




BC cases > Healthy controls
RS after radiation
BC cases > Healthy controls




1. BC cases (11)
2. First degree relative of BC
cases (22)




BC cases > Healthy controls
Relative of BC cases > Healthy controls




1. BC cases (130)




BC cases ↔ Healthy controls
RS after radiation
BC cases > Healthy controls




1. BC cases (39)










BC cases > Healthy controls
HDR
RS after radiation
BC cases > Healthy controls
LDR
RS after radiation
BC cases > Healthy controls
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Table 1 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using micronucleus assay (Continued)









1. Healthy BRCA2 mutation
carriers (18)
2. Non-carrier subjects from
BRCA1/2 families (17)
3. Healthy controls W/O




No difference across all groups
RS after radiation
Healthy BRCA2 mutation carrier > Healthy controls
Healthy BRCA2 mutation carrier ↔
Non-carrier subjects from BRCA1/2 families




1. Healthy BRCA1 mutations
carriers (18)
2. Healthy controls W/O




Healthy BRCA1 mutation carriers ↔ Healthy controls
RS after radiation
Healthy BRCA1 mutation carriers > Healthy controls
Gutierrez-Enriquez
et al. 2011 [138]
G2 MN
assay
1. 21 BRCA1 carriers (12 BC
and 9 Healthy)
2. 24 BRCA2 carriers (13 BC
and 11 Healthy)
3. Familial BC cases W/O
BRCA1/2 mutation (15)
4. 16 healthy controls W/O
familial history of BC (5 BC
and 11 Healthy)
Lymphocyte Mitomycin C RS after radiation
BRCA1 carriers ↔ Healthy controls
BRCA2 carriers > Healthy controls





1. Healthy BRCA1 mutation
carriers (25)





Healthy BRCA1 mutation carriers ↔ Non-carrier subjects
RS after radiation
Healthy BRCA1 mutation carriers ↔ Non-carrier subjects




1. BC cases (85)
2. BC cases with BRCA1
mutation (6)




BC with BRCA1 mutation ↔ Healthy controls
RS after radiation













3. Healthy relative W/O BRCA
mutation (10)
A. of BRCA1 (5)
B. of BRCA2 (5)
4. BC cases W/O BRCA
mutation (78)












BC cases > Healthy controls
BC with BRCA1/2 mutation ↔ BC W/O BRCA1/2
mutation




BC with BRCA1/2 mutation > Healthy controls
BC with BRCA1/2 mutation ↔ BC W/O BRCA1/2
mutation
Healthy relative with BRCA1/2 mutation ↔ Healthy
relative W/O BRCA1/2 mutation ↔ Healthy controls




1. Healthy BRCA1 mutation
carrier (13)
2. Healthy controls W/O




Healthy BRCA1 mutation carriers ↔ Healthy controls
RS after radiation
Healthy BRCA1 mutation carriers > Healthy controls




1. Healthy BRCA1 mutation
carrier (10)
2. Healthy BRCA2 mutation
carrier (9)
3. Healthy controls W/O




Healthy BRCA1 mutation carriers ↔ BRCA2 mutation
carriers
RS after radiation
Healthy BRCA1 mutation carriers ↔ BRCA2 mutation
carriers
Healthy BRCA1 mutation carriers > Healthy controls





1. Healthy BRCA1 mutation
carriers (12)





Healthy BRCA1 mutation carriers> Non-carrier subjects
from BRCA1 families
Non-carrier subjects from BRCA1 families ↔ Healthy
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Almost half of the studies which compared DNA re-
pair capacity of healthy BRCA1 mutation carrier with
non-carrier controls have reported no significant results
[13, 138] while others reported monoallelic BRCA1 or
BRCA2 mutations are associated with an enhanced ra-
diosensitivity [11, 130, 137, 138, 140, 141].
Although Rothfus et al. have suggested the MN
test as a screening test for carriers of a BRCA1 mu-
tation in breast cancer families, others failed to get
this result [142]. It seems this approach is not likely
to be useful for identification of BRCA carriers
from non-carrier with familial history of breast
cancer [130, 137, 140–142].
To determine whether MN assay is capable to
predict breast cancer patients with advanced radio-
therapy complications, two studies reported that the
level of MNi in cancer patients with an early ad-
verse skin reaction was significantly higher than the
unselected breast cancer group [12] and late reac-
tion [144]. However, Finnon et al. found no evi-
dence of a differential response between breast
cancer patients with marked or mild late adverse
responses to adjuvant breast radiotherapy [143].
Barber et al. also concluded no trends towards
increased chromosomal RS between acute and late
reactions following radiotherapy [134].
G2/0 chromosomal assay
After the MN assay, the chromosomal radiosensitivity
assay is a cell-cycle-based technique that has been used
extensively to investigate the association between human
chromosomal RS and susceptibility to cancer or radio-
therapy outcome. G2 assay most often applied on PHA-
stimulated peripheral blood T-lymphocytes although it
can measure the chromatid aberrations in any dividing
population of cells, such as skin fibroblasts. In this tech-
nique, cells are exposed to invitro-radiation during the
G2 phase of the cell cycle. The chromatid gaps and
breaks can be observed in cells that progressed to meta-
phase. Briefly, cells are cultured for 71–72 h before ir-
radiation. After 30 minutes of recovery, cells are treated
with colcemid for 1 h. The cells observed at metaphase
are those that were radiated in the G2 phase of the cell
cycle [146].
In all reported results, G2 assay able to detect the RS
differences in healthy donor and breast cancer patients
[135, 147–152] (Table 2). About BRCA1/2 carriers,
Ernestos et al. [153] and Baeyens et al. [139] have
Table 1 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using micronucleus assay (Continued)
Reference Marker Sample size Cell type Radiation
dose
Result
3. Healthy controls W/O
history of cancer (17)
controls
Radiotherapy complications




1. BC cases with ASR (31)










1. BC cases with ASR (9)
2. BC cases (50)
3. Healthy controls (16)




BC with ASR > Healthy controls
BC with ASR > BC cases
Slope of MN induction
BC with ASR > Healthy controls






BC cases with early reactions
(15)





Early reactions ↔ Late reactions
RS after radiation
Early reactions > Late reactions







Late reactions, 8-14 years
after radiotherapy (47)
LDR
ASR before radiotherapy (73)

















Acute reactions before radiotherapy ↔ 8-14 years after
radiotherapy
RS radiosensitivity, MN micronucleus, BC breast cancer, PBMC peripheral blood mononuclear cell, HDR high dose rate, LDR low dose rate, CBMN cytokinesis-block
micronucleus, ASR adverse early skin reaction, TNBC triple negative breast cancer, W/O without, Gr: gray
↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity
Sadeghi et al. Biological Procedures Online           (2020) 22:23 Page 14 of 28
Table 2 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using G0/G2 chromosomal assay
Reference Marker Sample size Cell type Radiation dose Result
Breast cancer
Ryabchenk et al. 2012 [148] G0 and G2 chromosomal
assay
1. BC cases (37) Lymphocyte G0 assay G0 assay & G2 assay
2. Healthy controls (44) 1.5 Gy Spontaneous RS
X-rays BC cases ↔ Healthy
controls
G2 assay G0 assay & G2 assay
0.5 Gy RS after radiation
X-rays BC cases > Healthy
controls
Bryant et al. 2012 [151] G2 chromosomal assay 1. BC cases (89) Lymphocyte 0.4 Gy RS after radiation
2. Healthy controls (96) γ-rays BC cases > Healthy
controls
Wang et al. (2012) [152] G2 chromosomal assay 1. BC cases (515) Lymphocyte 1.5 Gy non-Hispanic White
2. Healthy controls (402) γ-rays BC cases > Healthy
control
Mexican American
BC cases > Healthy
control
African Americans
BC cases ↔ Healthy
controls
Poggioli et al. 2010 [150] G0 & G2 chromosomal
assay
1. BC cases (23) Lymphocyte G2 assay G0 assay & G2 assay
2. Healthy controls (23) 0.4 Gy Spontaneous RS
X-rays BC cases ↔ Healthy
controls
G0 assay G0 assay & G2 assay
2 Gy RS after radiation
X-rays BC cases > Healthy
controls






Howe et al. 2005 [149] G2 chromosomal assay 1. BC cases (27) Lymphocyte 0.5 Gy RS after radiation
2. Healthy controls (14) γ-rays BC cases > Healthy
controls
Riches et al. 2001 [147] G2 chromosomal assay 1. BC cases (65) Lymphocyte 0.4 Gy RS after radiation
2. Healthy controls (66) γ-rays BC cases > Healthy
controls
Scott et al. 1999 [135] G2 chromosomal assay 1. BC cases (135) Lymphocyte 0.5 Gy Spontaneous RS
2. Healthy controls (105) X-rays Healthy control ↔
BC cases
RS after radiation
BC cases > Healthy
controls
BRCA1/2 mutation
Ernestos et al. 2010 [153] G2 chromosomal assay 1. BC cases with BRCA1/2
mutation (15)
Lymphocyte 1 Gy RS after radiation
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reported that breast cancer patients with BRCA1 or
BRCA2 mutations were not radiosensitive than healthy
women carrying no mutation.
Regarding the radiotherapy complications, no trends
towards increased chromosomal RS between acute and
late adverse reactions [134] or between marked and mild
late adverse reactions [143] following radiotherapy were
reported.
Comet assay
Comet Assay also called single cell gel electrophoresis
(SCGE), is a sensitive and rapid technique for detecting
Table 2 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using G0/G2 chromosomal assay (Continued)
Reference Marker Sample size Cell type Radiation dose Result
2. Healthy BRCA1/2
mutation carriers (5)
γ-rays BC with BRCA1/2
mutation >
Healthy controls
3. Healthy controls W/O




Baeyens et al (2002) [139] G2 chromosomal assay 1. BC cases with BRCA1/2
mutation (20)
Lymphocyte 0.4 Gy Spontaneous RS
A. BRCA1(11) γ-rays No difference
across all groups
B. BRCA2 (9) RS after radiation






A. BRCA1 (6) BC with BRCA2
mutation > healthy
controls
B. BRCA2 (6) Healthy relatives
with and W/O a
BRCA1 mutation
↔ healthy controls
3. Healthy relatives W/O
BRCA mutation (10)
A. of BRCA1 (5)
B. of BRCA2 (5)
4. BC cases W/O BRCA
mutation (78)
5. Healthy controls (58)
Radiotherapy complications
Finnon et al. 2012 [143] G2 chromosomal assay 1. BC cases with marked
reaction (31)
Lymphocyte 3.5 Gy RS after radiation
2. BC cases with mild
late adverse reaction (28)
X-rays Marked reaction ↔
Mild late adverse
reaction
Barber et al. 2000 [134] G2 chromosomal assay HDR
Acute reactions before
radiotherapy (116)





Late reactions, 8-14 years
after radiotherapy (26)
Lymphocyte HDR HDR
3.5 Gy γ-rays (dose




↔ 8-14 years after
radiotherapy
LDR
3.5 Gy γ-rays (dose





↔ 8-14 years after
radiotherapy
RS radiosensitivity, BC breast cancer, HDR high dose rate, LDR low dose rate, W/O without, Gr gray
↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity
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Table 3 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using comet assay
Reference Marker Sample size Cell type Radiation dose Result
Breast cancer
Lou et al. 2008 [133] Comet assay 1. BC cases (25) Lymphocyte 3-Gy Spontaneous RS
2. Healthy controls (25) X-rays Healthy controls ↔
BC cases
RS after radiation
BC cases > Healthy
controls
Shahidi et al. 2007 [157] Alkaline and Neutral
Comet assay
1. BC cases (35) Lymphocyte Alkaline Alkaline & Neutral
Comet assay
2. Healthy controls (29) 1 Gy Spontaneous RS
γ-rays BC cases > Healthy
controls
Neutral Alkaline & Neutral
Comet assay
2 Gy Initial RS
Alkaline & Neutral
Comet assay
γ-rays BC cases ↔ Healthy
controls
Djuzenova et al. 2006 [12] Comet assay 1. BC cases (50) PBMC 5 Gy Spontaneous RS
2. Healthy controls (16) X-rays BC cases ↔ Healthy
controls
Initial RS
BC cases ↔ Healthy
controls
Residue RS
BC cases ↔ Healthy
controls
Zhang et al. 2006 [156] Comet assay 1. Malignant breast
tumor (14)
PBMC 0.5 Gy Spontaneous RS
2. Benign breast
tumor (18)




Kotsopoulos et al. 2007 [13] Comet assay 1. Healthy BRCA1
mutation carriers (25)
Lymphocyte 2 Gy Spontaneous RS







Trenz et al (2002) [141] Comet assay 1. Healthy BRCA1
mutation carriers (5)
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chromosome aberration in eukaryotic cells. This tech-
nique was first introduced by Swedish researchers
Östling & Johansson in 1984 [154] and modified four
years later as Alkaline Comet Assay by Singh, et al.
[155]. The alkaline comet assay detects a wide range of
DNA damage including SSB, DSB, and alkaline- labile
sites. Another most common types of comet assay is the
neutral comet assay, which is more specific for detecting
DSB [156].
Three Studies evaluated the RS level in breast cancer
patients in comparison to healthy donors (Table 3). Two
studies found no significant difference in radiation-
induced DNA damage in cancer cases and healthy do-
nors [12, 157] while LOU et al. found a significantly
higher level of DNA damage in breast cancer patients
[133]. Similarly, in another study, Zhang et al. found ma-
lignant breast cancer patients showed a significant upper
rank of residual DNA double-strand than patients with
benign breast disease in neutral comet assay [156].
Healthy BRCA1 mutation carriers (heterozygous geno-
type) and non-carrier control had a similar mean tail
moment at baseline, and following g-irradiation. It seems
that the use of comet assay for the detection of DNA re-
pair capacity in healthy BRCA1 mutation carriers would
be limited [13].
For the predicative purpose of radiotherapy complica-
tion by comet assay, [12, 158], Oppitz et al. measured
the radiosensitivity in lymphocytes, PBMC, and fibro-
blast of breast cancer patients and compared with the
clinical acute reaction to radiotherapy. A significant as-
sociation between RS level and adverse early skin reac-
tion was found in lymphocytes cell, but not in PBMC
and Fibroblast [158].
Bio markers
In response to DSB, the histone H2 variant H2AX is
phosphorylated at its carboxyl-terminus on the con-
served serine 139 residues and named γ-H2AX [159]. γ
-H2AX is recognized as the biomarker of DSB, which
can be visualized within minutes of exposure [50]. Apart
from H2AX, P53 binding protein (53BP1) is another
damage sensor of DSBs [160] that is localized in damage
Table 3 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using comet assay (Continued)
Reference Marker Sample size Cell type Radiation dose Result
controls
Rothfus et al. (2000) [142] Comet assay 1. Healthy BRCA1
mutation carriers (12)
Lymphocyte 2 Gy RS after radiation
2. Non-carrier subjects
from BRCA1 families (10)
γ-rays No difference across
all groups
3. Healthy controls W/O
history of cancer (17)
Radiotherapy complications
Djuzenova et al. 2006 [12] Comet assay 1. BC cases with ASR (9) PBMC 5 Gy Spontaneous RS
2. BC cases (50) X-rays BC with ASR ↔ Healthy
controls
3. Healthy controls (16) BC with ASR ↔ BC cases
RS after radiation
BC with ASR ↔ Healthy
controls
BC with ASR ↔ BC cases
Oppitz et al. 2002 [158] Comet assay 1. BC cases (32) Lymphocyte &
Fibroblast
Lymphocyte Lymphocyte
A. Lymphocyte (30) 3Gy RS after radiation








RS radiosensitivity, BC breast cancer, PBMC peripheral blood mononuclear cell, W/O without, Gr gray
↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity
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Table 4 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using H2AX, P53bp biomarkers
Reference Marker Sample size Cell type Dose Result
Chua et al. 2014 [168] γH2AX/53BP1 1. BC cases (16) Lymphocyte 4 Gy Spontaneous RS




BC cases > Healthy controls
Djuzenova et al. 2013 [169] γH2AX 1. BC cases (57) PBMC 0.5 Gy & 2 Gy Spontaneous RS
2. Healthy controls (12) X-rays BC cases ↔ Healthy controls
Initial RS (0.5 Gy, 30min
post-radiation)
BC cases > Healthy controls
Residual RS (2 Gy, 24h
post-radiation)
BC cases > Healthy controls
Djuzenova et al. 2013 [169] 53BP1 1. BC cases (57) PBMC 0.5 Gy & 2 Gy Spontaneous RS
2. Healthy controls (12) X-rays BC cases ↔ Healthy controls
Initial RS (0.5 Gy, 30min
post-radiation)
BC cases ↔ Healthy controls
Residual (2 Gy, 24h
post-radiation)
BC > Healthy controls
BRCA1 mutation carriers
Kotsopoulos et al. 2007 [13] γ -H2AX 1. Healthy BRCA1
mutation carriers
Lymphocyte 2 Gy Spontaneous RS
2. Non-carrier controls (25) γ-rays Healthy BRCA1 mutation
carriers ↔ Non-carrier controls
RS after radiation
Healthy BRCA1 mutation
carriers ↔ Non-carrier controls
Radiotherapy complications
Chua et al. 2014 [168] γH2AX/53BP1 1. BC cases with minimal
late complication (8)
Lymphocyte 4 Gy Spontaneous RS
X-rays Marked late complication
↔ Minimal late complication





> Minimal late complication
Djuzenova et al. 2013 [169] H2AX 1. BC cases with adverse
acute skin reaction (6)
PBMC 0.5 Gy & 2 Gy Spontaneous RS
X-rays Adverse acute skin
reaction ↔ Normal
skin reaction
2. BC cases with normal
skin reaction (31)
Initial RS (0.5 Gy, 30min)
Adverse acute skin
reaction > Normal skin
reaction




Sadeghi et al. Biological Procedures Online           (2020) 22:23 Page 19 of 28
site and mediates the recruitment of BRCA1 by methyl-
ated H3 Lys 79 and signals chromatin/DNA damage
[161]. Following DNA damage, 53BP1 is rapidly phos-
phorylated by ATM on multiple residues such as serine
25 (Ser25) and serine 1778 (Ser1778) [162–164]. The
phosphorylated 53BP1 localizes in the damage site and
mediates the recruitment of BRCA 1[165–167].
Djuzenova et al. reported γ-H2AX assay may be useful
for screening the radiosensitivity in breast cancer pa-
tients (Table 4). In their study the number of γ-
H2AX foci was significantly higher in unselected
breast cancer patients compared to healthy volunteers
in both initial (0.5 Gy, 30 min) and residual (2 Gy, 24
h post-radiation) DNA damage. For 53bp1, a higher
level of foci was detected in the residual DNA damage
only [169]. Similarly, another study reported the cor-
relation between immunofluorescence of γ- H2AX/
53BP1 residual in breast cancer patients with healthy
volunteers [168].
Healthy BRCA1 mutation carriers and non-carriers
showed a similar level of γ-H2AX nuclear foci after ex-
posure to radiation, indicating γ-H2AX nuclear foci
assay is not likely able to distinguish women at a high
risk of hereditary breast cancer [13].
Increased chromosomal radiosensitivity, quantified
by γ-H2AX/53BP [168, 170] and γ-H2AX [169] im-
munofluorescence microscopy were observed in breast
cancer patients with an adverse acute skin reaction
compared to those with normal skin reaction after
radiotherapy. The controversial result appeared from
Finnon et al study, reported no significant association
between γ -H2AX foci number in breast cancer pa-
tients with a marked adverse reaction to adjuvant
breast radiotherapy with those manifesting mild late
adverse reactions [143].
Colony forming assay
Colony formation is another technique to measure the in-
trinsic cellular radiosensitivity of tumors. It is based on
the capability of a single cell to undergo multiple divisions
and grow into a colony form. In the presence of DNA
damage, cells fail to proliferate and lose their colony for-
mation capacity, whereas those with intact DNA are able
to survive during radiation, retain their reproductive abil-
ity and form visible colonies under a microscope [171].
Breast cancer patients with severe reactions to radio-
therapy were more sensitive to invitro iodine radiation
than healthy donors [172], but no evidence of a differen-
tial response was reported between breast cancer pa-
tients without radiotherapy complications and healthy
donors [172] (Table 5). Moreover, colony-forming assay
failed to detect the ionizing radiation sensitivity between
breast cancer patients with elevated acute reactions and
with average acute reactions [158].
Other assays
Telomere length assay
A telomere is a repetitive sequence structure at the end of
the chromosome [175]. This specialized structure is con-
sidered as a natural DSB and acts as an inhibitor of the
DSB repair pathways and DNA damage checkpoints [176].
During the division of somatic cells, the length of telo-
meres gradually gets shorter and this process is fascinated
by various endogenous and exogenous pathogenic factors
such as radiation, aging, smoking, mental stress and, etc.
[177–184]. Studies showed late generation (G5–G6)
Table 4 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using H2AX, P53bp biomarkers (Continued)
Reference Marker Sample size Cell type Dose Result
skin reaction
Finnon et al. 2012 [143] H2AX 1. BC cases with marked
adverse reaction (31)
Lymphocyte 4 Gy Residual RS (6 h & 24h
post-radiation)
X-rays Marked adverse reaction ↔
2. BC cases with mild
late adverse reaction (28)
Mild late adverse reaction
Chua et al. 2011 [170] γH2AX/53BP1 1. BC cases with severely
marked reaction (7)
Lymphocyte 0.5 and 4 Gy Initial RS (0.5 Gy, 30min
post-radiation)
X-rays Severely marked reaction
↔ Minimal skin reaction
2. BC cases with minimal
skin reaction (7)





RS radiosensitivity, BC breast cancer, PBMC peripheral blood mononuclear cell, W/O without, Gr gray
↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity
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mTR−/− mice were more sensitive to radiation compared
with G2 mTR−/− mice, which were also deficient in tel-
omerase activity but had longer telomere [185, 186].
Multiple methods have been developed to estimate the
study of telomere including; Terminal Restriction Frag-
mentation (TRF), Polymerase Chain Reaction-based Tech-
nique (PCR), Single Telomere Length Analysis (STELA),
Quantitative Fluorescence in situ Hybridization (Q-FISH).
TRF is often considered as the gold standard method
to study telomere [187]; however, this technique failed
to distinguish the level of chromosomal radiosensitivity
between newly diagnosed breast cancer patients and
healthy controls [174] (Table 5).
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH), is a very
highly sensitive technique that individual chromosomes
are printed using a specific probe [188]. The painted
chromosomes are easily visualized and the DNA damage
could be scored accurately in metaphase spreads. More-
over, different types of stable DNA damage including,
translocations, insertions and deletions, and unstable
damage such as di centric chromosomes, rings, and
acentric fragments could be differentiated [188]. Using
FISH assay, Auer et al. demonstrated that breast cancer
patients were significantly more sensitive compared to
healthy controls [173] but not in Barwell et al.’s study
[174] (Table 5).
In summary, the majority of studies confirmed the en-
hanced spontaneous & radiation-induced radiosensitivity
of breast cancer patients compared to healthy controls
(Table 6). Patients with sporadic breast cancer also had
lower DNA damage capacity compared to cancer-free
population, suggesting other low penetrance genes in-
volved in DNA repair pathways, and cell cycle and apop-
tosis cascades, such as p53bp, ATM, BARD1, and
Table 5 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy
complication, using other assays




3-color FISH 1. BC cases (67)
2. Healthy controls (62)
Lymphocyte 2 Gy Spontaneous RS
BC cases ↔ Healthy controls
RS after radiation





1. BC cases (212)
2. Healthy controls (1804)
WBC &
lymphocyte
1. caesium-137 source at
0.5/1 Gy, or mock
2. caesium-137 source at
4 Gy, or mock
RS after radiation
BC cases ↔ Healthy controls
West et al.
1995 [172]
Colony formation 1. BC cases with acute
complication (7)
2. BC cases with late
complication (6)
3. BC cases W/O
complication (8)







BC cases ↔ Healthy controls
LDR
RS after radiation




Colony formation 1. BC cases with elevated
acute reactions (6)
2. BC cases with average
acute reactions (17)
Fibroblast 5 Gy Spontaneous RS








Colony formation 1. BC cases with acute
complication (7)
2. BC cases with late
complication (6)
3. BC cases without
complication (8)







BC with acute/late complication
↔ Healthy controls




BC with acute/late complication
> Healthy controls
BC cases W/O complication ↔
Healthy controls
RS radiosensitivity, BC breast cancer, WBC white blood cell, HDR high dose rate, LDR low dose rate, W/O without, Gr: gray
↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity
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PALb2 are involved in increased radiation susceptibility
and could be a risk factor for both inherited and some
sporadic breast cancer development. Therefore, evaluat-
ing the overall individual capacity of repairing DNA
damages through different experimental approaches
could identify the hypersensitive patients and become a
marker of cancer proneness. Here we have found that
MN test, G0/2 chromosomal assay, and biomarkers pro-
vided more reproducible data compared to the other as-
says (Table 6).
BRCA1 and BRCA2 are highly penetrated genes in-
volved in the familial breast cancer development and
about 15 % of all familial breast cancer can be attributed
to a mutation in these genes. Using G2 MN and G2
chromosomal assays, some studies have reported the
lymphocyte of healthy BRCA1/2 mutation carriers (het-
erozygous genotype) are hypersensitive to invitro ioniz-
ing radiation compared to non-carriers without a history
of breast cancer. BRCA1/2 mainly function in the HR
pathway. Since the HR repair pathway exclusively takes
place in the late S and G2 phases of the cell cycle, in-
creased radiosensitivity in patients harbouring BRCA1/2
mutations is mostly detected when the radiation takes
place in the G2 phase. However, inconsistent evidence
also exists and other studies using comment assay, and
H2AX biomarker failed to detect the significant differ-
ences between these two groups as well.
Limited studies compared the radiosensitivity of healthy
BRCA1/2 mutation carriers and non-carriers in the BRCA
families (Table 6). Although Rothfus et al. have suggested
the MN test has a potential to be a screening test for car-
riers of a BRCA1 mutation in breast cancer families,
others failed to achieve this result. It seems this approach
is not likely to be useful for the identification of BRCA
carriers from non-carrier with familial history of breast
cancer. Developing novel radiosensitivity assays could be a
promising approach in evaluating the DNA repair capacity
of individuals with BRCA1/2 mutation and consider as a
predictive factor for overall increased risk mainly in the
relatives of breast cancer patients.
In addition, breast cancer patients with acute early reac-
tions to radiotherapies are more radiosensitive than those
with mild/no late reactions; however, inconsistent results
appear among different assays (Table 6). G2 chromosomal
assay failed to differentiate these differences, while most of
H2AX/p53bp biomarkers seem to be able to predict those
susceptible to radiotherapy complications.
Some studies have demonstrated that the presence of
BRCA1/2 mutations may increase the radiotherapy com-
plication but others not. In the reviewed population, the
genetic background of breast cancer patients has not been
defined; therefore, it is not possible to figure out whether
radiosensitivity assays are able to screen the BRCA1-2
mutation carrier for radiotherapy complications.
Conclusion
BRCA1 and BRCA2 are two highly penetrant genes in-
volved in inherited breast cancer and contribute to different
DNA damage pathways and cell cycle and apoptosis cas-
cades. Breast cancer patients are more radiosensitive com-
pared to healthy control; however, inconsistent results exist
about the ability of current radiosensitive techniques in
screening BRCA1/2 carriers or those susceptible to radio-
therapy complications. Therefore, developing novel radio-
sensitivity assays could be a promising approach for pre-
screening the BRCA1/2 mutation carriers and predict the
overall increased risk mainly in the relatives of breast can-
cer patients. Moreover, it can provide more evidence about
who is susceptible to manifest severe complication.
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